JCI Insight (Dec 2020)

Mitophagy protects β cells from inflammatory damage in diabetes

  • Vaibhav Sidarala,
  • Gemma L. Pearson,
  • Vishal S. Parekh,
  • Benjamin Thompson,
  • Lisa Christen,
  • Morgan A. Gingerich,
  • Jie Zhu,
  • Tracy Stromer,
  • Jianhua Ren,
  • Emma C. Reck,
  • Biaoxin Chai,
  • John A. Corbett,
  • Thomas Mandrup-Poulsen,
  • Leslie S. Satin,
  • Scott A. Soleimanpour

Journal volume & issue
Vol. 5, no. 24

Abstract

Read online

Inflammatory damage contributes to β cell failure in type 1 and 2 diabetes (T1D and T2D, respectively). Mitochondria are damaged by inflammatory signaling in β cells, resulting in impaired bioenergetics and initiation of proapoptotic machinery. Hence, the identification of protective responses to inflammation could lead to new therapeutic targets. Here, we report that mitophagy serves as a protective response to inflammatory stress in both human and rodent β cells. Utilizing in vivo mitophagy reporters, we observed that diabetogenic proinflammatory cytokines induced mitophagy in response to nitrosative/oxidative mitochondrial damage. Mitophagy-deficient β cells were sensitized to inflammatory stress, leading to the accumulation of fragmented dysfunctional mitochondria, increased β cell death, and hyperglycemia. Overexpression of CLEC16A, a T1D gene and mitophagy regulator whose expression in islets is protective against T1D, ameliorated cytokine-induced human β cell apoptosis. Thus, mitophagy promotes β cell survival and prevents diabetes by countering inflammatory injury. Targeting this pathway has the potential to prevent β cell failure in diabetes and may be beneficial in other inflammatory conditions.

Keywords